Pediatrix Medical Group Yönetim

Yönetim kriter kontrolleri 2/4

Pediatrix Medical Group CEO'su Jim Swift, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 2.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 29% maaş ve 71% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler € 2.41M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 4.3 yıldır.

Anahtar bilgiler

Jim Swift

İcra Kurulu Başkanı

US$2.2m

Toplam tazminat

CEO maaş yüzdesi	29.0%
CEO görev süresi	1.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jim Swift'un ücretlendirmesi Pediatrix Medical Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$254m
Jun 30 2024	n/a	n/a	-US$252m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$2m	US$650k	-US$60m
Sep 30 2023	n/a	n/a	US$88m
Jun 30 2023	n/a	n/a	US$95m
Mar 31 2023	n/a	n/a	US$98m
Dec 31 2022	US$1m	US$450k	US$63m

Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 2.24M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.63M ).

Tazminat ve Kazançlar: Jim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jim Swift (62 yo)

1.8yrs

Görev süresi

US$2,237,839

Tazminat

Dr. James D. Swift, M.D., also known as Jim, is Director of Brave Care, Inc. since October 2021. He had been the Chief Operating Officer at Pediatrix Medical Group, Inc. since May 2022 until December 31, 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Swift	CEO & Director	1.8yrs	US$2.24m	0.20% € 2.4m
Mary Ann Moore	Chief Administrative Officer	2.1yrs	US$1.83m	0.18% € 2.1m
Kasandra Rossi	Executive VP	less than a year	Veri yok	0.052% € 619.8k
John Pepia	Senior VP & Chief Accounting Officer	8.5yrs	US$1.43m	Veri yok
Cheryl VanPatten	Senior VP & Chief Information Officer	2.8yrs	Veri yok	Veri yok
Charles Lynch	Senior VP of Finance	no data	Veri yok	Veri yok
Meghan Lublin	Senior VP	3.3yrs	Veri yok	Veri yok
Debra McRoberts	Senior Vice President of People Services	less than a year	Veri yok	Veri yok
Daniel Corcoran	Senior Vice President of Administration & Managed Care	no data	Veri yok	Veri yok
Mike Ashford	President of Regional Operations (Central)	no data	Veri yok	Veri yok
Michael Dwyer	President of Regional Operations (South-Central)	no data	Veri yok	Veri yok
Nanette Sanders	Senior Vice President of Operations	no data	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: PDC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Swift	CEO & Director	1.7yrs	US$2.24m	0.20% € 2.4m
Mark Ordan	Chair	4.3yrs	US$554.45k	0.16% € 2.0m
Guy Sansone	Lead Independent Director	4.3yrs	US$295.00k	0.081% € 967.7k
Thomas McEachin	Independent Director	4.3yrs	US$252.50k	0.065% € 774.0k
Sylvia Young	Independent Director	1.5yrs	US$201.00k	0.035% € 413.5k
John Starcher	Independent Director	4.3yrs	US$230.00k	0.065% € 773.9k
Shirley Weis	Independent Director	4.3yrs	US$245.00k	0.043% € 510.3k
Gavin Molinelli	Board Observer	4.3yrs	Veri yok	Veri yok
Michael Rucker	Independent Director	5.5yrs	US$242.50k	0.069% € 823.7k
Laura Linynsky	Independent Director	2.5yrs	US$230.00k	0.023% € 275.5k

4.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PDC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Pediatrix Medical Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chair recently sold €401k worth of stock

Executive VP & CFO recently sold €461k worth of stock

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

Recent updates

Chair recently sold €401k worth of stock

Pediatrix Medical Group, Inc. Provides Goodwill and Long-Lived Asset Impairments Guidance for the Year Ending December 31, 2024

Pediatrix Medical Group, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Executive VP & CFO recently sold €461k worth of stock

New minor risk - Shareholder dilution

New minor risk - Share price stability

Pediatrix Medical Group, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.17 in 1Q 2023)

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings released: US$0.73 loss per share (vs US$0.75 profit in FY 2022)

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment deteriorates as stock falls 17%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.35 in 3Q 2022)

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 2Q 2022)

CEO & Director recently sold €172k worth of stock

Independent Director recently sold €238k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings released: EPS: US$0.17 (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$750 (vs US$1.27 in FY 2021)

Pediatrix Medical Group, Inc. Announces Executive Changes

CEO & Director recently sold €334k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold €368k worth of stock

Third quarter 2022 earnings released: EPS: US$0.35 (vs US$0.37 in 3Q 2021)

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix Medical Group, Inc. Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.36 in 2Q 2021)

Pediatrix Medical Group, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Mednax Announces Leadership Appointments

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.063 profit in 1Q 2021)

High number of new directors

MEDNAX, Inc. to Report Q1, 2022 Results on Apr 28, 2022

MEDNAX, Inc., Annual General Meeting, May 12, 2022

MEDNAX, Inc. Announces Resignation of Roger Mack Hinson as President of Pediatrix and Obstetrix Medical Group, Effective as of June 1, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

MEDNAX, Inc. Provides Earnings Guidance for the Year 2022

MEDNAX, Inc. to Report Q4, 2021 Results on Feb 17, 2022

MEDNAX, Inc. (NYSE:MD) acquired Night Lite Pediatrics.

Senior VP & Chief Accounting Officer recently sold €215k worth of stock

Third quarter 2021 earnings released: EPS US$0.37 (vs US$0.032 loss in 3Q 2020)

Senior VP & Chief Accounting Officer recently sold €268k worth of stock

Second quarter 2021 earnings released: EPS US$0.36 (vs US$0.085 in 2Q 2020)

New 90-day high: €23.60

Full year 2020 earnings released: US$0.12 loss per share (vs US$13.77 loss in FY 2019)

Revenue misses expectations

MEDNAX, Inc. to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €20.00

Federman & Sherwood Files First Data Breach Case Against MedNax, Inc. and Pediatrix Medical Group

New 90-day high: €19.60

New 90-day high: €17.20

New 90-day high: €16.60

Revenue misses expectations

Third quarter 2020 earnings released: US$0.032 loss per share

New 90-day low: €12.80

New 90-day low: €14.10

Executive VP recently sold €352k worth of stock

New 90-day high - €17.30

MEDNAX, Inc. to Report Q2, 2020 Results on Jul 30, 2020

MEDNAX, Inc. Announces Executive Change

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Dynamic Index

MEDNAX, Inc.(NYSE:MD) dropped from Russell 1000 Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi